In The News Posted July 24, 2022 Share Posted July 24, 2022 - Sur la base des résultats de l'étude de phase 3 BOSTON, l'autorisation de mise sur le marché permet d'étendre l'indication du myélome multiple - - L'approbation fait suite à l'avis positif du Comité européen des médicaments à usage humain (CMUH), rendu en mai 2022 - NEWTON, Mass. et...View the full article Link to comment Share on other sites More sharing options...
Recommended Posts
Create an account or sign in to comment
You need to be a member in order to leave a comment
Create an account
Sign up for a new account in our community. It's easy!
Register a new accountSign in
Already have an account? Sign in here.
Sign In Now